Emergent BioSolutions cuts 2026 revenue and EBITDA guidance as Q3 sales fall 52%
The company also disclosed a CFO transition, a debt repurchase, and a $24 million CYFENDUS contract modification as it narrows its full-year outlook.
SEC filing (23)
3 stories
The company also disclosed a CFO transition, a debt repurchase, and a $24 million CYFENDUS contract modification as it narrows its full-year outlook.
SEC filing (23)
BioReference Health will sell its clinical and anatomic pathology testing business, including the 4Kscore prostate cancer test, to Laboratory Corporation of America Holdings.
SEC filing
OPKO Health determined on October 1, 2026 that holders of its 3.75% Convertible Senior Notes due 2029 can convert through December 31, 2026, and said it will settle in common stock.
SEC filing